At the experimental endpoint, the DN4.99 TCR-T cell transfer resulted in the survival of NALM-6 cells expressing lower levels of CD1c than tumors of control mice (Fig. 8f), confirming the CD1c-dependent mechanism of tumor recognition and the strong anti-leukemia effect of this TCR. This evidence concerns the gene CD1C and neoplasm.